[ad_1]
Pharmaceutical company Cipla said it plans to continue growing in all its key markets during the current fiscal year and plans to file more than 12 abbreviated new drug applications during this fiscal year. period.
Highlighting the priorities for fiscal year 2010, the company said in the Indian market, it is studying a strong growth of existing franchises, including respiratory, and chronic therapies such as diabetes, cardio and health care. women, according to the latest presentation from a Cipla investor.
For the US market, where the company has seen significant growth driven by the ramp-up of key differentiated products during fiscal year 19, it plans to step up launches from previous fiscal years and to introduce more products during the year 20. While pursuing specialized investments.
On another key market of South Africa, during current fiscal year Cipla seeks to strengthen its OTC activities.
In the rest of the world market, the company will focus on the continuation of the market.
For the current fiscal year, the company will focus on complex and differentiated badets and plan to file more than 12 abbreviated new drug (ANDA) applications, while ensuring the compliance of all its facilities in the world .
Cipla recorded a net profit of Rs 1,492.44 crores for the 2018-19 financial year, compared with Rs 1,416.57 crores in 2017-2018. It was a crore of 15,219.25 Rs for the previous exercise.
Get the results of the Lok Sabha 2019 direct election, riding counts, news, views and badysis
Follow our live blog on Lok Sabha's election results here.
[ad_2]
Source link
